Home
INMB
INMB News

Latest INmune Bio Inc. Common stock (INMB) News on November 23, 2025

INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference

GlobeNewswire

5 days ago

INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference

INmune Bio (INMB) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Zacks

17 days ago

INmune Bio (INMB) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Wall Street says tokenization will change global markets. Gold is next.

Yahoo Finance

22 days ago

Wall Street says tokenization will change global markets. Gold is next.

US negotiating power is strong across the globe, except in China

Yahoo Finance Video

22 days ago

US negotiating power is strong across the globe, except in China

DeepSeek, Qwen AI Besting ChatGPT, Grok, Gemini In AI Crypto Trading Challenge

Benzinga

22 days ago

DeepSeek, Qwen AI Besting ChatGPT, Grok, Gemini In AI Crypto Trading Challenge

Furloughed federal workers face delays getting unemployment pay during shutdown

Associated Press Finance

22 days ago

Furloughed federal workers face delays getting unemployment pay during shutdown

Veralto Corporation (NYSE:VLTO) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Simply Wall St.

22 days ago

Veralto Corporation (NYSE:VLTO) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

The No. 1 Reason New Businesses Fail, According to a Shark Tank Investor

GOBankingRates

22 days ago

The No. 1 Reason New Businesses Fail, According to a Shark Tank Investor

Ryerson Holding (NYSE:RYI) Is Due To Pay A Dividend Of $0.1875

Simply Wall St.

22 days ago

Ryerson Holding (NYSE:RYI) Is Due To Pay A Dividend Of $0.1875

2 Big Tech Stocks Just Announced Stock Splits. Here's What You Need to Know.

Motley Fool

22 days ago

2 Big Tech Stocks Just Announced Stock Splits. Here's What You Need to Know.

INmune Bio Inc (INMB) Q3 2025 Earnings Call Highlights: Regulatory Progress and Financial ...

GuruFocus.com

23 days ago

INmune Bio Inc (INMB) Q3 2025 Earnings Call Highlights: Regulatory Progress and Financial ...

INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update

GlobeNewswire

24 days ago

INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update

INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025

GlobeNewswire

a month ago

INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025

INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025

GlobeNewswire

a month ago

INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025

MT Newswires

5 months ago

Traders Assess Potential US-Canada Trade Deal, Lifting US Equity Futures Pre-Bell

MT Newswires

5 months ago

INmune Bio's XPro Fails to Meet Primary Cognitive Endpoint in Phase 2 Alzheimer's Trial; Shares Fall

Investing.com

5 months ago

INmune Bio stock plummets after mixed Phase 2 Alzheimer’s trial results

MT Newswires

5 months ago

Top Premarket Decliners

INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer’s Disease

GlobeNewswire

5 months ago

INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer’s Disease

INmune Bio's US$24m Market Cap Fall Books Insider Losses

Simply Wall St.

5 months ago

INmune Bio's US$24m Market Cap Fall Books Insider Losses

MT Newswires

5 months ago

INmune Bio to Raise $19 Million in Direct Offering to Institutional Investors

INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire

5 months ago

INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

MT Newswires

5 months ago

Top Premarket Gainers

INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30th

GlobeNewswire

5 months ago

INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer’s on Monday, June 30th

XPro™ Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer’s Disease: Supported by Department of Defense

GlobeNewswire

5 months ago

XPro™ Reduces Amyloid and Enhances Behavior Post Traumatic Brain Injury in an Animal Model of Alzheimer’s Disease: Supported by Department of Defense

INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference

GlobeNewswire

6 months ago

INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference

INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update

GlobeNewswire

6 months ago

INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update

INmune Bio Inc (INMB) Q1 2025: Everything You Need To Know Ahead Of Earnings

GuruFocus.com

7 months ago

INmune Bio Inc (INMB) Q1 2025: Everything You Need To Know Ahead Of Earnings

INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th

GlobeNewswire

7 months ago

INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th

MT Newswires

7 months ago

INmune Bio Receives Favorable Opinion from USPTO on CORDStrom Patent Application

INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology

GlobeNewswire

7 months ago

INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology

MT Newswires

7 months ago

INmune Bio Collaborating With Cell and Gene Therapy Catapult to Scale Manufacturing

INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness

GlobeNewswire

7 months ago

INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness

INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study

GlobeNewswire

8 months ago

INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study

INmune Bio Inc (INMB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

GuruFocus.com

8 months ago

INmune Bio Inc (INMB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update

GlobeNewswire

8 months ago

INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update

INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025

GlobeNewswire

8 months ago

INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025

Why INmune Bio, Inc. (INMB) is Skyrocketing So Far in 2025

Insider Monkey

9 months ago

Why INmune Bio, Inc. (INMB) is Skyrocketing So Far in 2025

INmune Bio, Inc. (NASDAQ:INMB) most popular amongst individual investors who own 36% of the shares, institutions hold 28%

Simply Wall St.

9 months ago

INmune Bio, Inc. (NASDAQ:INMB) most popular amongst individual investors who own 36% of the shares, institutions hold 28%

INmune Bio price target raised to $23 from $22 at Scotiabank

TipRanks

9 months ago

INmune Bio price target raised to $23 from $22 at Scotiabank

INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer

GlobeNewswire

9 months ago

INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer

MT Newswires

9 months ago

INmune Bio to Seek Approval of Skin Disorder Treatment in US, UK, Europe

INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

GlobeNewswire

9 months ago

INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Why INmune Bio Inc (INMB) Is Skyrocketing So Far In 2025

Insider Monkey

10 months ago

Why INmune Bio Inc (INMB) Is Skyrocketing So Far In 2025

INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans

GlobeNewswire

10 months ago

INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans

Raymond James Predicts Up to ~930% Rally for These 2 ‘Strong Buy’ Stocks

TipRanks

10 months ago

Raymond James Predicts Up to ~930% Rally for These 2 ‘Strong Buy’ Stocks

INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt

GlobeNewswire

a year ago

INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt

OmniScience and INmune Bio Partner for Alzheimer’s Trial

Exec Edge

a year ago

OmniScience and INmune Bio Partner for Alzheimer’s Trial

MT Newswires

a year ago

INmune Bio Partners With OmniScience to Accelerate Alzheimer's Trial

OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower

Business Wire

a year ago

OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower

INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease

GlobeNewswire

a year ago

INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease

INmune Bio Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.48 loss in 3Q 2023)

Simply Wall St.

a year ago

INmune Bio Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.48 loss in 3Q 2023)

INmune Bio Inc (INMB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ...

GuruFocus.com

a year ago

INmune Bio Inc (INMB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges and ...

INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

GlobeNewswire

a year ago

INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

INmune Bio Inc (INMB) Q3 2024 Earnings Report Preview: What To Look For

GuruFocus.com

a year ago

INmune Bio Inc (INMB) Q3 2024 Earnings Report Preview: What To Look For

INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB

GlobeNewswire

a year ago

INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB

Highbridge Capital Management's Strategic Acquisition of INmune Bio Inc Shares

GuruFocus.com

a year ago

Highbridge Capital Management's Strategic Acquisition of INmune Bio Inc Shares

INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination

GlobeNewswire

a year ago

INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination

INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024

GlobeNewswire

a year ago

INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024

Insider Stock Buying Reaches US$951.2k On INmune Bio

Simply Wall St.

a year ago

Insider Stock Buying Reaches US$951.2k On INmune Bio

INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit

GlobeNewswire

a year ago

INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit

INmune Bio Inc (INMB) Q2 2024 Earnings Call Highlights: Promising Advances Amid Rising Costs

GuruFocus.com

a year ago

INmune Bio Inc (INMB) Q2 2024 Earnings Call Highlights: Promising Advances Amid Rising Costs

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 10/01/2024

MT Newswires

a year ago

INmune Bio Closes Enrollment for Phase 2 XPro Trial in Early Alzheimer's Disease

INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease

GlobeNewswire

a year ago

INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease

INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort

GlobeNewswire

a year ago

INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort

MT Newswires

a year ago

INmune Bio Says AD02 Trial for Alzheimer's Disease Reveals Strong Performance of EMACC Cognitive Measure

INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints

GlobeNewswire

a year ago

INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints

MT Newswires

a year ago

INmune Bio Launches $13 Million Registered Direct Offering of Common Shares, Warrants

INmune Bio Announces $13.0 Million Registered Direct Offering

GlobeNewswire

a year ago

INmune Bio Announces $13.0 Million Registered Direct Offering

INmune Bio, Inc.'s (NASDAQ:INMB) top owners are individual investors with 44% stake, while 23% is held by institutions

Simply Wall St.

a year ago

INmune Bio, Inc.'s (NASDAQ:INMB) top owners are individual investors with 44% stake, while 23% is held by institutions

INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference

GlobeNewswire

a year ago

INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference

INmune Bio Second Quarter 2024 Earnings: US$0.51 loss per share (vs US$0.36 loss in 2Q 2023)

Simply Wall St.

a year ago

INmune Bio Second Quarter 2024 Earnings: US$0.51 loss per share (vs US$0.36 loss in 2Q 2023)

INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update

GlobeNewswire

a year ago

INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update

INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients

GlobeNewswire

a year ago

INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients

INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024

GlobeNewswire

a year ago

INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024

INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer

GlobeNewswire

a year ago

INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer

Shareholders Will Probably Be Cautious Of Increasing INmune Bio, Inc.'s (NASDAQ:INMB) CEO Compensation At The Moment

Simply Wall St.

a year ago

Shareholders Will Probably Be Cautious Of Increasing INmune Bio, Inc.'s (NASDAQ:INMB) CEO Compensation At The Moment

INmune Bio’s unique Alzheimer’s trial endpoint receives validation

Clinical Trials Arena

a year ago

INmune Bio’s unique Alzheimer’s trial endpoint receives validation

INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial

GlobeNewswire

a year ago

INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial

MT Newswires

a year ago

Sector Update: Health Care Stocks Higher in Afternoon Trading

MT Newswires

a year ago

INmune Bio to Join Russell 3000 Index in July

INmune Bio Inc. to Join Russell 3000® Index

GlobeNewswire

a year ago

INmune Bio Inc. to Join Russell 3000® Index

INmune Bio, Inc. (NASDAQ:INMB) Q1 2024 Earnings Call Transcript

Insider Monkey

2 years ago

INmune Bio, Inc. (NASDAQ:INMB) Q1 2024 Earnings Call Transcript

INmune Bio First Quarter 2024 Earnings: EPS Misses Expectations

Simply Wall St.

2 years ago

INmune Bio First Quarter 2024 Earnings: EPS Misses Expectations

INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update

GlobeNewswire

2 years ago

INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update

INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9

GlobeNewswire

2 years ago

INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9

INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years

GlobeNewswire

2 years ago

INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years

INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

GlobeNewswire

2 years ago

INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

INmune Bio Independent Director Acquires 80% More Stock

Simply Wall St.

2 years ago

INmune Bio Independent Director Acquires 80% More Stock

INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire

2 years ago

INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay

GlobeNewswire

2 years ago

INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay

INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering

GlobeNewswire

2 years ago

INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering

INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024

GlobeNewswire

2 years ago

INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024

INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript

Insider Monkey

2 years ago

INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript

INmune Bio Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

2 years ago

INmune Bio Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

INmune Bio Inc (INMB) Posts Year-End Earnings, Reveals Net Loss Amidst Clinical Advancements

GuruFocus.com

2 years ago

INmune Bio Inc (INMB) Posts Year-End Earnings, Reveals Net Loss Amidst Clinical Advancements

INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update

GlobeNewswire

2 years ago

INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update

INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28

GlobeNewswire

2 years ago

INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28

INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy

GlobeNewswire

2 years ago

INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy

Share on Social Networks: